Summary: Researchers have identified a toxic protein complex formed by NMDA receptors (NMDAR) and TRPM4 ion channels that drives neuronal death and accelerates disease progression in Alzheimer’s disease. In a mouse model, a novel small molecule, FP802, disrupted this “death complex,” preventing cognitive decline, preserving synapses and mitochondrial integrity, and reducing amyloid‑beta accumulation. These results suggest a new therapeutic direction for Alzheimer’s and other neurodegenerative disorders such as ALS.
Key Facts
- Toxic complex identified: The NMDAR/TRPM4 interaction creates a neurotoxic signaling unit that promotes neuronal death and disease progression.
- Drug candidate: FP802, a TwinF interface inhibitor, breaks apart this complex in mice and protects cognition, synapses, and mitochondria.
- Novel therapeutic strategy: Targets a downstream cell‑death mechanism rather than directly removing amyloid plaques, offering a complementary approach to existing therapies.
Source: Heidelberg University
A new molecular mechanism that drives Alzheimer’s disease progression has been revealed by a team led by Prof. Dr. Hilmar Bading at Heidelberg University.
Working with collaborators from Shandong University (China) and using the 5xFAD mouse model of Alzheimer’s disease, the researchers showed that a protein‑protein complex composed of extrasynaptic NMDARs and TRPM4 channels mediates toxic glutamate signaling. This NMDAR/TRPM4 complex — previously recognized in other contexts — is markedly increased in Alzheimer’s mice and promotes synaptic loss, mitochondrial dysfunction, and eventual neuronal death that underlies cognitive decline.
To disrupt this harmful interaction the team tested FP802, a small‑molecule TwinF interface inhibitor developed by Prof. Bading’s group at the Institute of Neurobiology (IZN) and advanced together with the biotech spinout FundaMental Pharma. FP802 binds the TwinF contact surface that mediates TRPM4’s interaction with NMDARs, preventing the two proteins from forming the toxic complex and thereby detoxifying extrasynaptic NMDAR signaling.
Oral FP802 treatment in 5xFAD mice blocked the rise in NMDAR/TRPM4 complex formation and produced broad neuroprotective effects. Treated animals showed preserved learning and memory in cognitive tests, maintained dendritic complexity, and avoided the typical synapse loss seen in untreated disease models. Mitochondrial structure and function were largely protected, and the characteristic accumulation of amyloid‑beta plaques was significantly reduced.
Prof. Bading emphasizes that this strategy differs from approaches aimed primarily at clearing amyloid. Instead of directly targeting amyloid production or removal, TwinF interface inhibitors block a downstream, disease‑amplifying mechanism: the NMDAR/TRPM4 death complex. By interrupting this feedback loop, the inhibitor not only prevents cell death but also appears to limit processes that feed further amyloid pathology.
The research group previously reported similar protective effects of FP802 in models of amyotrophic lateral sclerosis (ALS), where the same NMDAR/TRPM4 interaction contributes to neuronal loss. These findings indicate that TwinF interface inhibition could represent a broadly applicable pharmacological principle for slowing or halting progression across multiple neurodegenerative diseases.
Despite promising preclinical data, the authors caution that clinical application remains in the future. Comprehensive pharmacological development, toxicology testing, and human clinical trials are required before FP802 or related compounds could be considered for patient use. In collaboration with FundaMental Pharma, the team plans to optimize FP802’s properties and carry out the necessary development work.
Funding: The study was supported by the German Research Foundation, the European Research Council, the former Federal Ministry of Education and Research (Germany), the National Natural Science Foundation of China, and the province of Shandong.
The full results are published in Molecular Psychiatry.
About this genetics and Alzheimer’s disease research news
Author: Ute Mueller‑Detert
Source: Heidelberg University
Contact: Ute Mueller‑Detert – Heidelberg University
Image credit: Neuroscience News
Original Research (open access): “The NMDAR/TRPM4 death complex is a major promoter of disease progression in the 5xFAD mouse model of Alzheimer’s disease” by Hilmar Bading et al., Molecular Psychiatry. DOI: 10.1038/s41380-025-03143-5
Abstract
The NMDAR/TRPM4 death complex is a major promoter of disease progression in the 5xFAD mouse model of Alzheimer’s disease
Alzheimer’s disease is a progressive neurodegenerative disorder defined by cognitive decline and neuron loss, with hallmark features that include amyloid‑beta plaques and neurofibrillary tangles. The molecular mediators linking amyloid and tau pathology to neuronal death have remained incompletely understood. Using the 5xFAD mouse model, the authors examined the role of the recently described death signaling complex formed by extrasynaptic NMDARs and the TRPM4 cation channel.
Formation of the NMDAR/TRPM4 complex increases toxic glutamate signaling implicated in Alzheimer’s pathogenesis. This complex was elevated in 5xFAD brains and its formation was prevented by oral FP802, a TwinF interface inhibitor that disrupts the NMDAR/TRPM4 interaction. FP802 treatment preserved cognitive performance in memory tasks, maintained dendritic and synaptic integrity, reduced amyloid plaque burden, and protected mitochondrial structure and function. These findings identify the NMDAR/TRPM4 death complex as a central promoter of disease progression and support TwinF interface inhibitors as a novel therapeutic avenue, complementary to strategies that remove amyloid‑beta.